NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Corbus Pharmaceuticals logo
$2.67 -0.07 (-2.70%)
As of 10:20 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Advanced

Key Stats

Today's Range
$2.63
▼
$2.88
50-Day Range
$2.74
▼
$8.24
52-Week Range
$2.62
▼
$12.88
Volume
54,388 shs
Average Volume
551,553 shs
Market Capitalization
$54.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.67
Consensus Rating
Moderate Buy

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity.

Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.

Founded in 2014, Corbus previously focused on inflammatory and fibrotic diseases before shifting its research toward oncology and metabolic disorders. The company is led by co-founder and Chief Executive Officer Yuval Cohen.

AI Generated. May Contain Errors.

Corbus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

CRBP MarketRank™: 
3.6102760317 of 5 stars

Corbus Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 343rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Corbus Pharmaceuticals has a consensus price target of $35.67, representing about 1,230.8% upside from its current price of $2.68.

  • Amount of Analyst Coverage

    Corbus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Corbus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($6.29) to ($5.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corbus Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corbus Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corbus Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.01% of the float of Corbus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Corbus Pharmaceuticals has recently increased by 19.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Corbus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corbus Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Corbus Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    4 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corbus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,180.00 in company stock.

  • Percentage Held by Insiders

    3.50% of the stock of Corbus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corbus Pharmaceuticals' insider trading history.
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRBP Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Corbus Pharmaceuticals Reports Positive Oral Obesity Drug Data
See More Headlines

CRBP Stock Analysis - Frequently Asked Questions

Corbus Pharmaceuticals' stock was trading at $8.14 at the beginning of the year. Since then, CRBP stock has decreased by 67.1% and is now trading at $2.68.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.27) by $0.54.

Corbus Pharmaceuticals (CRBP) raised $20 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 20,206,636 shares at $1.00 per share.

Corbus Pharmaceuticals' top institutional investors include RA Capital Management L.P. (9.29%), Marshall Wace LLP (1.50%), State Street Corp (1.40%) and Goldman Sachs Group Inc. (0.62%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Nishant C Saxena, Ian Hodgson, Winston Kung, Yong Ben, Anne Altmeyer and John Kenneth Jenkins.
View institutional ownership trends
.

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Aurora Cannabis (ACB), Tesla (TSLA), Alibaba Group (BABA) and Cronos Group (CRON).

Company Calendar

Last Earnings
11/10/2026
Today
11/19/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRBP
CIK
1595097
Employees
36
Year Founded
2009

Price Target and Rating

High Price Target
$48.00
Low Price Target
$23.00
Potential Upside/Downside
+1,237.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.54 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-100.96%
Return on Assets
-82.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.40
Quick Ratio
3.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.11 per share
Price / Book
0.65

Miscellaneous

Outstanding Shares
20,610,000
Free Float
19,886,000
Market Cap
$54.97 million
Optionable
Optionable
Beta
2.80

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CRBP) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners